Lumida
/MBX
⌘K
MBX Biosciences Inc

MBX Biosciences Inc

MBX
$59.02USD-3.15%-1.92 today

MARKET CAP

2.8B

P/E (TTM)

FWD P/E

DAY RANGE

$58 – $62

52W RANGE

$10
$73

AI Summary

Stalk
Sell NowMedium

MBX is in a Stage 4 decline following support failure through key EMAs, establishing a medium-term bearish bias. Short-term price remains below declining EMAs with no exhaustion pattern, aligning with a momentum strategy that favors selling into rallies around the broken support cluster near the 9/20/50 EMA zone. The long-term uptrend stays intact above the rising 200-day SMA.

  • Promising Phase 3 trial for canvuparatide in Q3 2026 after strong one-year data.
  • $418.6M in cash and securities funds operations into 2029, reducing near-term dilution.
  • Q2 2026 net loss of $37.1M ($0.78/share) vs $19.4M prior year, missing consensus by $0.10.
Full analysis →
Insider Trades9 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Aug 4, 2026SellMBXSalomon AzoulayChief Medical Officer370$65.77$2.8B-18.75%+512.88%$24.3K-2.51%Buy Now
May 8, 2026SellMBXSalomon AzoulayChief Medical Officer140,006$25.01$2.8B-18.75%+512.88%$3.5M+0.00%Buy Now
May 6, 2026SellMBXSalomon AzoulayChief Medical Officer231$29.54$2.8B-18.75%+512.88%$6.8K-1.54%Buy Now
May 6, 2026SellMBXP. Kent HawrylukPresident & CEO607$29.54$2.8B-18.75%+512.88%$17.9K-0.08%Buy Now
Mar 13, 2026BuyMBXP. Kent HawrylukPresident & CEO18,500$28.41$2.8B-18.75%+512.88%$525.7K+3.95%Buy Now
Feb 26, 2026BuyMBXP. Kent HawrylukPresident & CEO28,768$16.00$2.8B-18.75%+512.88%$460.3K+3.64%Buy Now
Oct 24, 2025BuyMBXP. Kent HawrylukPresident & CEO182,859$3.25$2.8B-18.75%+512.88%$594.3K+29.92%Buy Now
Oct 20, 2025BuyMBXP. Kent HawrylukPresident & CEO20,000$13.64$2.8B-18.75%+512.88%$272.8K+4.46%Buy Now
Feb 4, 2025BuyMBXP. Kent HawrylukPresident & CEO50,000$10.69$2.8B-18.75%+512.88%$534.5K+7.80%Buy Now